Moderna’s Spikevax has higher risk of heart inflammation than Pfizer’s Comirnaty: Study

The risk of heart inflammation is up to two or three times higher among people who took Moderna’s COVID-19 vaccine, Spikevax, compared to those who took Pfizer’s Comirnaty, a new study has concluded.

The research, published in the Journal of the American College of Cardiology, is one of several that continue to track the effects of COVID-19 vaccines nearly two years after their initial rollout.